Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.